B. Wynne

发表

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

Kimberly Smith, Melissa Crawford, J. V. van Wyk, 2019, Journal of acquired immune deficiency syndromes.

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet

B. Wynne, R. Mehta, J. Piscitelli, 2020, Clinical pharmacology : advances and applications.

Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media

A. Hoberman, R. Dagan, B. Wynne, 2001, The Pediatric infectious disease journal.

Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.

B. Wynne, E. Berkowitz, S. Finegold, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food

S. Piscitelli, S. Weller, B. Wynne, 2014, Journal of acquired immune deficiency syndromes.

Large Dosage Amoxicillin/Clavulanate, Compared With Azithromycin, for the Treatment of Bacterial Acute Otitis Media in Children

A. Hoberman, R. Dagan, B. Wynne, 2005, The Pediatric infectious disease journal.

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

D. Podzamczer, S. Walmsley, J. Kilby, 2015, Journal of acquired immune deficiency syndromes.

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection

J. Rockstroh, P. Cahn, A. Antinori, 2021, AIDS.

Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults

B. Wynne, M. Holton, A. Buchanan, 2017, Clinical pharmacology in drug development.

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

G. McComsey, M. Aboud, B. Wynne, 2017, AIDS.

Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.

S. Scholten, B. Wynne, M. Ait-Khaled, 2021, Journal of acquired immune deficiency syndromes.

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2

B. Wynne, J. Llibre, R. van Solingen-Ristea, 2022, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic Bronchitis

S. Sethi, B. Wynne, J. Breton, 2005, Antimicrobial Agents and Chemotherapy.

Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.

T. File, B. Wynne, J. Garau, 2005, International journal of antimicrobial agents.

Efﬁcacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic Bronchitis

S. Sethi, B. Wynne, J. Breton, 2004 .

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

T. File, M. Poole, B. Wynne, 2002, International journal of antimicrobial agents.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

S. Walmsley, C. Orrell, Kimberly Smith, 2017, The lancet. HIV.

Multinational study of pneumococcal serotypes causing acute otitis media in children

G. Yothers, S. Pelton, S. Kaplan, 2002, The Pediatric infectious disease journal.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants

Rajendra Singh, B. Wynne, Allen Wolstenholme, 2021, Clinical pharmacology in drug development.

Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

J. Lake, M. Aboud, B. Wynne, 2017, Antiviral therapy.

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

Kimberly Smith, Melissa Crawford, M. Aboud, 2019, Journal of acquired immune deficiency syndromes.

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

B. Wynne, R. Gulminetti, H. Tsai, 2021 .

Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.

G. Woodnutt, B. Wynne, C. Kaye, 2004, The Journal of antimicrobial chemotherapy.

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

A. Zolopa, M. Ramgopal, Tulika Singh, 2021, AIDS.

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

J. Rockstroh, P. Cahn, A. Antinori, 2020, Journal of Infection and Public Health.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects

S. Piscitelli, B. Wynne, N. Arya, 2014, Journal of clinical pharmacology.

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection

B. Wynne, R. Mehta, Allen Wolstenholme, 2018, Antimicrobial Agents and Chemotherapy.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

C. Hung, F. Castelli, M. Aboud, 2018, The Lancet.

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

B. Wynne, N. Arya, T. Eley, 2016, BMC Infectious Diseases.

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

S. Piscitelli, S. Weller, B. Wynne, 2016, European Journal of Clinical Pharmacology.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

S. Walmsley, N. Clumeck, B. Wynne, 2013, The New England journal of medicine.

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

J. Routy, S. De Wit, Kimberly Smith, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

B. Wynne, J. Humphreys, G. Bowers, 2016, Journal of acquired immune deficiency syndromes.

Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study

M. Ramgopal, B. Wynne, B. Akil, 2015, Antiviral therapy.

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Keith Nangle, Kimberly Smith, M. Aboud, 2021, Antimicrobial agents and chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

D. Podzamczer, C. Orkin, Kimberly Smith, 2019, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

J. Rockstroh, P. Cahn, A. Antinori, 2019, Journal of acquired immune deficiency syndromes.

Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

J. Routy, J. V. Wyk, M. Aboud, 2020 .

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

C. Hung, J. Slim, J. Eron, 2019, Journal of Infection and Public Health.

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

P. Tebas, B. Wynne, C. Hicks, 2015, AIDS.

Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials

B. Wynne, M. van der Kolk, R. Grove, 2021, HIV research & clinical practice.

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

Kimberly Smith, B. Wynne, A. Tenorio, 2019, Open Forum Infectious Diseases.

Pharmacokinetically Enhanced Amoxicillin/Clavulanate (2,000/125 mg) in Acute Bacterial Rhinosinusitis caused by Streptococcus Pneumoniae, Including Penicillin-Resistant Strains

M. Poole, B. Wynne, J. Anon, 2006, Ear, nose, & throat journal.

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

S. Piscitelli, S. Weller, B. Wynne, 2013, European Journal of Clinical Pharmacology.

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

F. Raffi, L. Curtis, B. Wynne, 2014, HIV clinical trials.

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

C. Hung, J. Slim, J. Eron, 2020, Journal of acquired immune deficiency syndromes.

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens

C. Katlama, R. Batterham, S. Scholten, 2023, Open forum infectious diseases.

Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and -2 Randomized Clinical Trials.

C. Orkin, Kimberly Smith, B. Wynne, 2020, Journal of acquired immune deficiency syndromes.

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

B. Wynne, R. Mehta, H. Crauwels, 2023, British journal of clinical pharmacology.

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

S. Piscitelli, B. Wynne, Mark Johnson, 2014, British journal of clinical pharmacology.

Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by

Kimberly Smith, M. Aboud, B. Wynne, 2016 .

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

S. Walmsley, N. Clumeck, B. Wynne, 2013, The New England journal of medicine.